MyFinsight
Home
Blog
About
Contact
Download
Download image
Eylea Net Product
Sales
$473,100K
(-35.72%↓ Y/Y)
EYLEAHD
$468,400K
US
$286,100K
(48.62%↑ Y/Y)
Non Us
$152,100K
(64.25%↑ Y/Y)
EYLEAHDAnd EYLEA-US
$941,500K
LIBTAYONet Product Sales
$438,200K
(53.70%↑ Y/Y)
Praluent Net Product
Sales-US
$66,600K
(17.25%↑ Y/Y)
Evkeeza-US
$45,700K
(47.90%↑ Y/Y)
Other Products
$31,300K
Lynozyfic
$11,200K
Collaboration Revenue
$1,899,700K
(24.07%↑ Y/Y)
Product
$1,534,500K
(8.40%↑ Y/Y)
Product And Service
Other
$171,200K
(109.04%↑ Y/Y)
Revenues
$3,605,400K
(19.04%↑ Y/Y)
Other income
(expense), net
$201,200K
(-37.52%↓ Y/Y)
Income from operations
$642,900K
(8.65%↑ Y/Y)
Total other income
(expense)
$188,300K
(-39.90%↓ Y/Y)
Total expenses
$2,962,500K
(21.56%↑ Y/Y)
Interest expense
$12,900K
(48.28%↑ Y/Y)
Income before income
taxes
$831,200K
(-8.15%↓ Y/Y)
Research and development
$1,543,500K
(16.28%↑ Y/Y)
Selling, general, and
administrative
$647,700K
(2.32%↑ Y/Y)
Cost of goods sold,
collaboration and contract...
$373,400K
(40.64%↑ Y/Y)
Cost of goods sold,
collaboration and contract...
$296,000K
(48.89%↑ Y/Y)
Acquired in-process
research and development
$101,900K
(728.46%↑ Y/Y)
Net income
$727,200K
(-10.08%↓ Y/Y)
Gain (loss) on
foreign currency...
$200K
(118.18%↑ Y/Y)
Income tax expense
$104,000K
(8.00%↑ Y/Y)
Comprehensive income
$661,600K
(-21.77%↓ Y/Y)
Unrealized (loss) gain on
debt securities
-$65,800K
(-272.70%↓ Y/Y)
Back
Back
Income Statement
REGN_BIG copy-svg-svg-svg
REGENERON PHARMACEUTICALS, INC. (REGN)
REGN_BIG copy-svg-svg-svg
REGENERON PHARMACEUTICALS, INC. (REGN)
source: myfinsight.com